{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:38:55Z","timestamp":1790671135477,"version":"4.1.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T00:00:00Z","timestamp":1434672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0130339","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T18:09:12Z","timestamp":1434737352000},"page":"e0130339","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells"],"prefix":"10.1371","volume":"10","author":[{"given":"Nassera","family":"Aouali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Broukou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Bosseler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Keunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Schlesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam","family":"Janji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Palissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Stordeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Berchem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,6,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4065\/78.1.15","article-title":"Multiple myeloma: how far have we come?","volume":"78","author":"KC Anderson","year":"2003","journal-title":"Mayo Clinic proceedings"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"A Palumbo","year":"2011","journal-title":"The New England journal of medicine"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"M Chesi","year":"2012","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14728214.2012.713345","article-title":"Emerging biological insights and novel treatment strategies in multiple myeloma","volume":"17","author":"M Gentile","year":"2012","journal-title":"Expert opinion on emerging drugs"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/SPC.0b013e3283565c56","article-title":"Multiple myeloma: improved outcomes with new therapeutic approaches","volume":"6","author":"S Eshaghian","year":"2012","journal-title":"Current opinion in supportive and palliative care"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"JE Bolden","year":"2006","journal-title":"Nature reviews Drug discovery"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0092-8674(00)00118-5","article-title":"Signaling to chromatin through histone modifications","volume":"103","author":"P Cheung","year":"2000","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/13543784.2012.668883","article-title":"Panobinostat for the treatment of multiple myeloma","volume":"21","author":"P Neri","year":"2012","journal-title":"Expert opinion on investigational drugs"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13148-010-0012-4","article-title":"Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy","volume":"1","author":"JM Wagner","year":"2010","journal-title":"Clinical epigenetics"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/00001813-199711000-00007","article-title":"Sodium valproate inhibits in vivo growth of human neuroblastoma cells","volume":"8","author":"J Cinatl Jr","year":"1997","journal-title":"Anti-cancer drugs"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1073\/pnas.94.1.237","article-title":"Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor","volume":"94","author":"P Tontonoz","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2741\/4021","article-title":"PPAR gamma, bioactive lipids, and cancer progression","volume":"17","author":"GT Robbins","year":"2012","journal-title":"Front Biosci"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"37731","DOI":"10.1074\/jbc.R100034200","article-title":"PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth","volume":"276","author":"ED Rosen","year":"2001","journal-title":"The Journal of biological chemistry"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Eeckhoute J, Oger F, Staels B, Lefebvre P. Coordinated Regulation of PPARgamma Expression and Activity through Control of Chromatin Structure in Adipogenesis and Obesity. PPAR research. 2012: 164140.","DOI":"10.1155\/2012\/164140"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1074\/jbc.272.29.18250","article-title":"Functional interactions between the estrogen receptor and the transcription activator Sp1 regulate the estrogen-dependent transcriptional activity of the vitellogenin A1 io promoter","volume":"272","author":"SR Batistuzzo de Medeiros","year":"1997","journal-title":"The Journal of biological chemistry"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0092-8674(95)90193-0","article-title":"15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma","volume":"83","author":"BM Forman","year":"1995","journal-title":"Cell"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1749-6632.2003.tb05964.x","article-title":"Histone deacetylases: unique players in shaping the epigenetic histone code","volume":"983","author":"S Thiagalingam","year":"2003","journal-title":"Annals of the New York Academy of Sciences"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Tsukahara T. The Role of PPARgamma in the Transcriptional Control by Agonists and Antagonists. PPAR research. 2012: 362361.","DOI":"10.1155\/2012\/362361"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc3214","article-title":"The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention","volume":"12","author":"JM Peters","year":"2012","journal-title":"Nature reviews Cancer"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Sikka S, Chen L, Sethi G, Kumar AP. Targeting PPARgamma Signaling Cascade for the Prevention and Treatment of Prostate Cancer. PPAR research. 2012: 968040.","DOI":"10.1155\/2012\/968040"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-2141.2009.07902.x","article-title":"Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells","volume":"147","author":"N Aouali","year":"2009","journal-title":"British journal of haematology"},{"key":"ref22","first-page":"319","article-title":"Body condition scoring: a rapid and accurate method for assessing health status in mice","volume":"49","author":"MH Ullman-Cullere","year":"1999","journal-title":"Laboratory animal science"},{"key":"ref23","first-page":"1234","article-title":"The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy","volume":"91","author":"R Bataille","year":"2006","journal-title":"Haematologica"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"M Gottlicher","year":"2001","journal-title":"The EMBO journal"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2011.40.6967","article-title":"The era of combination therapy in myeloma","volume":"30","author":"S Lonial","year":"2012","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1182\/blood-2012-06-434571","article-title":"Treating myeloma: the future is already here!","volume":"120","author":"O Landgren","year":"2012","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1038\/480S38a","article-title":"Animal models: Towards a myeloma mouse","volume":"480","author":"S DeWeerdt","year":"2011","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"RA Kyle","year":"2009","journal-title":"Leukemia"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/1940-6207.CAPR-10-0138","article-title":"Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model","volume":"3","author":"A Sharabi","year":"2010","journal-title":"Cancer prevention research"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2141.2008.07387.x","article-title":"In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor","volume":"143","author":"P Neri","year":"2008","journal-title":"British journal of haematology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/1541-7786.MCR-10-0471","article-title":"Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Molecular cancer research","volume":"9","author":"X Chen","year":"2011","journal-title":"MCR"},{"key":"ref32","first-page":"395","article-title":"Histone deacetylase inhibitors sodium butyrate and valproic acid delay spontaneous cell death in purified rat retinal ganglion cells","volume":"17","author":"J Biermann","year":"2011","journal-title":"Molecular vision"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ajh.21815","article-title":"Serum free light chain analysis","volume":"85","author":"MS Davids","year":"2010","journal-title":"American journal of hematology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12185-012-1164-0","article-title":"Serial measurement of free light chain detects poor response to therapy early in three patients with multiple myeloma who have measurable M-proteins","volume":"96","author":"S Fuchida","year":"2012","journal-title":"International journal of hematology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1158\/1078-0432.CCR-08-0326","article-title":"Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention","volume":"15","author":"F Ondrey","year":"2009","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1476-5381.2011.01383.x","article-title":"Peroxisome proliferator-activated receptors and cancer: challenges and opportunities","volume":"164","author":"J Youssef","year":"2011","journal-title":"British journal of pharmacology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1124\/mol.104.007732","article-title":"Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells","volume":"67","author":"JW Huang","year":"2005","journal-title":"Molecular pharmacology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1006\/bbrc.2001.5491","article-title":"Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators","volume":"286","author":"F Yin","year":"2001","journal-title":"Biochemical and biophysical research communications"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1101\/gad.1263305","article-title":"Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes","volume":"19","author":"HP Guan","year":"2005","journal-title":"Genes & development"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.febslet.2011.05.007","article-title":"Epigenetic codes of PPARgamma in metabolic disease","volume":"585","author":"S Sugii","year":"2011","journal-title":"FEBS letters"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"13600","DOI":"10.1074\/jbc.M409468200","article-title":"The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis","volume":"280","author":"C Yu","year":"2005","journal-title":"The Journal of biological chemistry"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/377397a0","article-title":"Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor","volume":"377","author":"AJ Horlein","year":"1995","journal-title":"Nature"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.279.5351.700","article-title":"Differential use of CREB binding protein-coactivator complexes","volume":"279","author":"R Kurokawa","year":"1998","journal-title":"Science"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12185-013-1290-3","article-title":"Histone deacetylase inhibitors in the treatment for multiple myeloma","volume":"97","author":"T Hideshima","year":"2013","journal-title":"International journal of hematology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0130339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T16:28:49Z","timestamp":1717950529000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0130339"}},"subtitle":[],"editor":[{"given":"Claire M.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,19]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0130339","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,19]]}}}